Myelin lipids have long been thought to play intriguing roles in the pathogenesis of multiple sclerosis (MS). This review summarizes current understanding of the molecular basis of MS with emphasis on the: (i.) physico-chemical properties, organization and accessibility of the lipids and their distribution within the myelin multilayer; (ii.) characterization of myelin lipid structures, and structure–function relationships relevant to MS mechanisms, and; (iii.) immunogenic and other features of lipids in MS including molecular mimicry, lipid enzyme genetic knockouts, glycolipid-reactive NKT cells, and monoclonal antibody-induced remyelination. New findings associate anti-lipid antibodies with pathophysiological biomarkers and suggest clinical utility. The structure of CD1d-lipid complexed with the lipophilic invariant T cell receptor (iTCR) may be crucial to understanding MS pathogenesis, and design of lipid antigen-specific therapeutics. Novel immuno-modulatory tools for treatment of autoimmune diseases including MS in which there is both constraint of inflammation and stimulation of remyelination are now emerging.
1 Chekhonin VP Semenova AV Gurina OI Dmitrieva TB . Myelin oligodendrogliocyte glycoprotein: the structure, functions, role in pathogenesis of demyelinating disorders. Biomed Khim2003; 49: 411–423.
3 Jaskiewicz E . Epitopes on myelin proteins recognized by autoantibodies present in multiple sclerosis patients. Postepy Hig Med Dosw (Online)2004; 58: 472–482.
4.
4 Johns TG Bernard CC . The structure and function of myelin oligodendrocyte glycoprotein. J Neurochem1999; 72: 1–9.
5.
5 Meinl E Hohlfeld R . Immunopathogenesis of multiple sclerosis: MBP and beyond. Clin Exp Immunol2002; 128: 395–397.
6.
6 Tzakos AG Troganis A Theodorou V . Structure and function of the myelin proteins: current status and perspectives in relation to multiple sclerosis. Curr Med Chem2005; 12: 1569–1587.
7.
7 Sobel RA Greer JM Kuchroo VK . Minireview: autoimmune responses to myelin proteolipid protein. Neurochem Res1994; 19: 915–921.
8.
8 Musse AA Harauz G . Molecular “negativity” may underlie multiple sclerosis: role of the myelin basic protein family in the pathogenesis of MS. Int Rev Neurobiol2007; 79: 149–172.
9.
9 Quarles RH . Myelin sheaths: glycoproteins involved in their formation, maintenance and degeneration. Cell Mol Life Sci2002; 59: 1851–1871.
10.
10 Rosetti CM; Maggio B; Oliveira RG; . The self-organization of lipids and proteins of myelin at the membrane interface. Molecular factors underlying the microheterogeneity of domain segregation. Biochim Biophys Acta 2008; 1778: 1665–1675.
11.
11 Stoffel W Bosio A . Myelin glycolipids and their functions. Curr Opin Neurobiol1997; 7: 654–661.
12.
12 Tartaglia MC Narayanan S De Stefano N . Choline is increased in pre-lesional normal appearing white matter in multiple sclerosis. J Neurol2002; 249: 1382–1390.
13.
13 Qin J Goswami R Balabanov R Dawson G . Oxidized phosphatidylcholine is a marker for neuroinflammation in multiple sclerosis brain. J Neurosci Res2007; 85: 977–984.
14.
14 Ohler B; Graf K; Bragg R; . Role of lipid interactions in autoimmune demyelination. Biochim Biophys Acta 2004; 1688: 10–17.
15.
15 Shamshiev A Donda A Carena I Mori L Kappos L De Libero G . Self glycolipids as T-cell autoantigens. Eur J Immunol1999; 29: 1667–1675.
16.
16 Pender MP Csurhes PA Wolfe NP . Increased circulating T cell reactivity to GM3 and GQ1b gangliosides in primary progressive multiple sclerosis. J Clin Neurosci2003; 10: 63–66.
17.
17 De Libero G Mori L . How T lymphocytes recognize lipid antigens. FEBS Lett2006; 580: 5580–5587.
18.
18 Matà S Lolli F Söderström M Pinto F Link H . Multiple sclerosis is associated with enhanced B cell responses to the ganglioside GD1a. Mult Scler1999; 5: 379–388.
19.
19 Lutterotti A Berger T Reindl M . Biological markers for multiple sclerosis. Curr Med Chem2007; 14: 1956–1965.
20.
20 Berger T Reindl M . Biomarkers in multiple sclerosis: role of antibodies. Dis Markers2006; 22: 207–212.
21.
21 Acarin N Rio J Fernández AL . Different antiganglioside antibody pattern between relapsing–remitting and progressive multiple sclerosis. Acta Neurol Scand1996; 93: 99–103.
22.
22 Miyake S Yamamura T . Therapeutic potential of glycolipid ligands for natural killer (NK) T cells in the suppression of autoimmune diseases. Curr Drug Targets Immune Endocr Metabol Disord2005; 5: 315–322.
23.
23 Lalazar G Preston S Zigmond E Ben Yáacov A Ilan Y . Glycolipids as immune modulatory tools. Mini Rev Med Chem2006; 6: 1249–1253.
24.
24 Lutterotti A Sospedra M Martin R . Antigen-specific therapies in MS – current concepts and novel approaches. J Neurol Sci2008; 274: 18–22.
25.
25 Stoffel W . The myelin membrane of the central nervous system-essentail macromolecular structure and function. Angew Chem Int Ed Engl1990; 29: 958–978.
26.
26 Deber CM Reynolds SJ . Central nervous system myelin: structure, function, and pathology. Clin Biochem1991; 24: 113–134.
27.
27 Norton WT Autilio LA . The lipid composition of purified bovine brain myelin. J Neurochem1966; 13: 213–222.
28.
28 Fewster ME Hirono H Mead JF . Lipid composition of myelin in multiple sclerosis. J Neurol1976; 213: 119–131.
29.
29 Linington C Rumsby MG . Accessibility of galactosyl ceramides to probe reagents in central nervous system myelin. J Neurochem1980; 35: 983–992.
30.
30 Caspar DL Kirschner DA . Myelin membrane structure at 10 a resolution. Nat New Biol1971; 231: 46–52.
31.
31 Morell P Quarles RH . Myelin formation, structure and biochemistry. In: GJ Siegel BW Agranoff RW Albers SK Fisher MD Uhler , (eds), Basic neurochemistry: molecular, cellular and medical aspects, 6th ed.New York: Lippincott-Raven; 1999. pp. 69–93.
32.
32 Wheeler D Bandaru VV Calabresi PA Nath A Haughey NJ . A defect of sphingolipid metabolism modifies the properties of normal appearing white matter in multiple sclerosis. Brain2008; 131: 3092–3102.
33.
33 Joffe S Rapport MM Graf L . Identification of an organ specific lipid hapten in brain. Nature1963; 197: 60–62.
34.
34 Rostami A Eccleston PA Silberberg DH . Generation and biological properties of a monoclonal antibody to galactocerebroside. Brain Res1984; 298: 203–208.
35.
35 Saida T Saida K Silberberg DH . Demyelination produced by experimental allergic neuritis serum and anti-galactocerebroside antiserum in CNS cultures. An ultrastructural study. Acta Neuropathol1979; 48: 19–25.
36.
36 Rostami AM Burns JB Eccleston PA Manning MC Lisak RP Silberberg DH . Search for antibodies to galactocerebroside in the serum and cerebrospinal fluid in human demyelinating disorders. Ann Neurol1987; 22: 381–383.
37.
37 Dasgupta S Levery SB Hogan EL . 3-O-acetyl-sphingosine-series myelin glycolipids: characterization of novel 3-O-acetyl-sphingosine galactosylceramide. J Lipid Res2002; 43: 751–761.
38.
38 Bennion B Dasgupta S Hogan EL Levery SB . Characterization of novel myelin components 3-O-acetyl-sphingosine galactosylceramides by electrospray ionization Q-TOF MS and MS/CID-MS of Li+ adducts. J Mass Spectrom2007; 42: 598–620.
40 Xu Y Ramu Y Lu Z . Removal of phospho-head groups of membrane lipids immobilizes voltage sensors of K+ channels. Nature2008; 451: 826–829.
41.
41 Yu RK Ledeen RW . Gangliosides of human, bovine, and rabbit plasma. J Lipid Res1972; 13: 680–686.
42.
42 Yu RK Bieberich E Xia T Zeng G . Regulation of ganglioside biosynthesis in the nervous system. J Lipid Res2004; 45: 783–793.
43.
43 Kamoshita S Aron AM Suzuki K Suzuki K . Infantile niemann-pick disease. A chemical study with isolation and characterization of membranous cytoplasmic bodies and myelin. Am J Dis Child1969; 117: 379–394.
44.
44 Ledeen RW Yu RK Eng LF . Gangliosides of human myelin: sialosylgalactosylceramide (G7) as a major component. J Neurochem1973; 21: 829–839.
45.
45 Suzuki K Kamoshita S Eto Y Tourtellotte WW Gonatas JO . Myelin in multiple sclerosis. Composition of myelin from normal-appearing white matter. Arch Neurol1973; 28: 293–297.
46.
46 Kishimoto Y Radin NS Tourtellotte WW Parker JA Itabashi HH . Gangliosides and glycerophospholipids in multiple sclerosis white matter. Arch Neurol1967; 16: 41–54.
47.
47 Yu RK Ledeen RW Eng LF . Ganglioside abnormalities in multiple sclerosis. J Neurochem1974; 23: 169–174.
48.
48 Alling C Vanier MT Svennerholm L . Lipid alterations in apparently normal white matter in multiple sclerosis. Brain Res1971; 35: 325–336.
49.
49 Arnon R Crisp E Kelley R Ellison GW Myers LW Tourtellotte WW . Anti-ganglioside antibodies in multiple sclerosis. J Neurol Sci1980; 46: 179–186.
50.
50 Feix JB Khatri B McQuillen MP Koethe SM . Immune reactivity against membranes containing ganglioside GM1 in chronic-progressive multiple sclerosis: observation by spin-membrane immunoassay. Immunol Commun1984; 13: 465–474.
51.
51 Endo T Scott DD Stewart SS Kundu SK Marcus DM . Antibodies to glycosphingolipids in patients with multiple sclerosis and SLE. J Immunol1984; 132: 1793–1797.
52.
52 Kasai N Pachner AR Yu RK . Anti-glycolipid antibodies and their immune complexes in multiple sclerosis. J Neurol Sci1986; 75: 33–42.
53.
53 Mathiesen T von Holst H Fredrikson S . Total, anti-viral, and anti-myelin IgG subclass reactivity in inflammatory diseases of the central nervous system. J Neurol1989; 236: 238–242.
54.
54 Stevens A Weller M Wiethölter H . CSF and serum ganglioside antibody patterns in MS. Acta Neurol Scand1992; 86: 485–489.
55.
55 Bech E Jakobsen J Orntoft TF . ELISA-type titertray assay of IgM anti-GM1 autoantibodies. Clin Chem1994; 40: 1331–1334.
56.
56 Borsellino G Koul O Placido R . Evidence for a role of gammadelta T cells in demyelinating diseases as determined by activation states and responses to lipid antigens. J Neuroimmunol2000; 107: 124–129.
57.
57 Villar LM Sádaba MC Roldán E . Intrathecal synthesis of oligoclonal IgM against myelin lipids predicts an aggressive disease course in MS. J Clin Invest2005; 115: 187–194.
58.
58 Sadatipour BT Greer JM Pender MP . Increased circulating antiganglioside antibodies in primary and secondary progressive multiple sclerosis. Ann Neurol1998; 44: 980–983.
59.
59 Valentino P Labate A Nisticò R . Anti-GM1 antibodies are not associated with cerebral atrophy in patients with multiple sclerosis. Mult Scler2009; 15: 114–115.
60.
60 Giovannoni G Morris PR Keir G . Circulating antiganglioside antibodies are not associated with the development of progressive disease or cerebral atrophy in patients with multiple sclerosis. Ann Neurol2000; 47: 684–685.
61.
61 Nagai Y Kanfer JN Tourtellotte WW . Preliminary observations of gangliosides of normal and multiple sclerosis cerebrospinal fluid. Neurology1973; 23: 945–948.
62.
62 Zaprianova E Deleva D Ilinov P . Serum ganglioside patterns in multiple sclerosis. Neurochem Res2001; 26: 95–100.
63.
63 Zaprianova E Majtényi K Deleva D . Serum IgG and IgM ganglioside GM1 antibodies in patients with multiple sclerosis. Ideggyogy Sz2004; 57: 94–99.
64.
64 Sela BA Konat G Offner H . Elevated ganglioside concentration in serum and peripheral blood lymphocytes from multiple sclerosis patients in remission. J Neurol Sci1982; 54: 143–148.
65.
65 Lebrun M Cherayil G . Plasma gangliosides in multiple sclerosis. Neurosci Lett1976; 2: 171–176.
66.
66 Marconi S De Toni L Lovato L . Expression of gangliosides on glial and neuronal cells in normal and pathological adult human brain. J Neuroimmunol2005; 170: 115–121.
67.
67 Chang A Tourtellotte WW Rudick R Trapp BD . Premyelinating oligodendrocytes in chronic lesions of multiple sclerosis. N Engl J Med2002; 346: 165–173.
68.
68 Ruf P Jäger M Ellwart J Wosch S Kusterer E Lindhofer H . Two new trifunctional antibodies for the therapy of human malignant melanoma. Int J Cancer2004; 108: 725–732.
69.
69 Bjartmar C Kinkel RP Kidd G Rudick RA Trapp BD . Axonal loss in normal-appearing white matter in a patient with acute MS. Neurology2001; 57: 1248–1252.
70.
70 Bjartmar C Trapp BD . Axonal degeneration and progressive neurologic disability in multiple sclerosis. Neurotox Res2003; 5: 157–164.
71.
71 Bosio A Binczek E Stoffel W . Functional breakdown of the lipid bilayer of the myelin membrane in central and peripheral nervous system by disrupted galactocerebroside synthesis. Proc Natl Acad Sci U S A1996; 93: 13280–13285.
72.
72 Bosio A Binczek E Haupt WF Stoffel W . Composition and biophysical properties of myelin lipid define the neurological defects in galactocerebroside- and sulfatide-deficient mice. J Neurochem1998; 70: 308–315.
73.
73 Ilyas AA Chen ZW Cook SD . Antibodies to sulfatide in cerebrospinal fluid of patients with multiple sclerosis. J Neuroimmunol2003; 139: 76–80.
74.
74 Wilson R Tocher DR . Lipid and fatty acid composition is altered in plaque tissue from multiple sclerosis brain compared with normal brain white matter. Lipids1991; 26: 9–15.
75.
75 Yahara S Kawamura N Kishimoto Y Saida T Tourtellotte WW . A change in the cerebrosides and sulfatides in a demyelinating nervous system. Development of the methodology and study of multiple sclerosis and Wallerian degeneration. J Neurol Sci1982; 54: 303–315.
76.
76 Marbois BN Faull KF Fluharty AL Raval-Fernandes S Rome LH . Analysis of sulfatide from rat cerebellum and multiple sclerosis white matter by negative ion electrospray mass spectrometry. Biochim Biophys Acta2000; 1484: 59–70.
77.
77 Eng LF Chao FC Gerstl B Pratt D Tavaststjerna MG . The maturation of human white matter myelin. Fractionation of the myelin membrane proteins. Biochemistry1968; 7: 4455–4465.
78.
78 Jatzkewitz H . A new method for the quantitative ultramicrodetermination of sphingolipids from the brain. Hoppe Seylers Z Physiol Chem1964; 336: 25–39.
79.
79 Cuzner ML Norton WT . Biochemistry of demyelination. Brain Pathol1996; 6: 231–242.
80.
80 Calabrese V Bella R Testa D . Increased cerebrospinal fluid and plasma levels of ultraweak chemiluminescence are associated with changes in the thiol pool and lipid-soluble fluorescence in multiple sclerosis: the pathogenic role of oxidative stress. Drugs Exp Clin Res1998; 24: 125–131.
81.
81 Kanter JL Narayana S Ho PP . Lipid microarrays identify key mediators of autoimmune brain inflammation. Nat Med2006; 12: 138–143.
82.
82 Kolodny EH De Gasperi R Gama Sosa MA Weinreb HJ Herbert J . Antisulfatide immunoglobulin G is elevated in the serum of multiple sclerosis patients. Ann Neurol1995; 38: 340.
83.
83 Ryberg B . Multiple specificities of antibrain antibodies in multiple sclerosis and chronic myelopathy. J Neurol Sci1978; 38: 357–382.
84.
84 Kirschning E Rutter G Huckhagel C Ellhof I Hohenberg H . A sulfatide-reactive monoclonal antibody derived from a patient with multiple sclerosis binds to myelin in situ. Ann N Y Acad Sci1997; 815: 455–458.
85.
85 Kirschning E Rutter G Uhlig H Dernick R . A sulfatide-reactive human monoclonal antibody obtained from a multiple sclerosis patient selectively binds to the surface of oligodendrocytes. J Neuroimmunol1995; 56: 191–200.
86.
86 Webb HE . Antiglycolipid autoimmunity. Possible viral etiology of multiple sclerosis. In: S Specter M Bendinelli H Friedman , (eds), Neuropathogenic viruses and immunity.New York: Plenum Press; 1992. pp. 277–302.
87.
87 Dyer CA Benjamins JA . Galactocerebroside and sulfatide independently mediate Ca2+ responses in oligodendrocytes. J Neurosci Res1991; 30: 699–711.
88.
88 Rosenbluth J Moon D . Dysmyelination induced in vitro by IgM antisulfatide and antigalactocerebroside monoclonal antibodies. J Neurosci Res2003; 71: 104–109.
89.
89 Rosenbluth J Schiff R Liang WL Dou W . Antibody-mediated CNS demyelination II. Focal spinal cord lesions induced by implantation of an IgM antisulfatide-secreting hybridoma. J Neurocytol2003; 32: 265–276.
90.
90 Prineas JW . The neuropathology of multiple sclerosis. In: Koster, JC, (ed), Handbook of clinical neurology, Vol. 3. demyelinating diseases. New York: Elsevier; 1985. pp. 213–257.
91.
91 Aotsuka S Okawa-Takatsuji M Uwatoko S Yokohari R Ikeda Y Toda G . Antibodies against sulphatide in sera from patients with autoimmune rheumatic diseases. Clin Exp Immunol1992; 87: 438–443.
92.
92 Ilyas AA Mithen FA Chen ZW Cook SD . Search for antibodies to neutral glycolipids in sera of patients with Guillain–Barre syndrome. J Neurol Sci1991; 102: 67–75.
93.
93 Nemni R Fazio R Quattrini A Lorenzetti I Mamoli D Canal N . Antibodies to sulfatide and to chondroitin sulfate C in patients with chronic sensory neuropathy. J Neuroimmunol1993; 43: 79–85.
94.
94 Avila JL Rojas M Carrasco H . Elevated levels of antibodies against sulphatide are present in all chronic chagasic and dilated cardiomyopathy sera. Clin Exp Immunol1993; 92: 460–465.
95.
95 Prineas JW Connell F . Remyelination in multiple sclerosis. Ann Neurol1979; 5: 22–31.
96.
96 Prineas JW Kwon EE Goldenberg PZ . Multiple sclerosis. Oligodendrocyte proliferation and differentiation in fresh lesions. Lab Invest1989; 61: 489–503.
97.
97 Roussel V Yi F Jauberteau MO . Prevalence and clinical significance of anti-phospholipid antibodies in multiple sclerosis: a study of 89 patients. J Autoimmun2000; 14: 259–265.
98.
98 Cordoliani MA Michon-Pasturel U Rerat K . Multiple sclerosis and antiphospholipid antibodies: study of 62 consecutive patients. Rev Med Interne1998; 19: 635–639.
99.
99 D’Olhaberriague L Levine SR Salowich-Palm L . Specificity, isotype, and titer distribution of anticardiolipin antibodies in CNS diseases. Neurology1998; 51: 1376–1380.
100.
100 Tourbah A Clapin A Gout O . Systemic autoimmune features and multiple sclerosis: a 5-year follow-up study. Arch Neurol1998; 55: 517–521.
101.
101 Lolli F Matá S Baruffi MC Amaducci L . Cerebrospinal fluid anti-cardiolipin antibodies in neurological diseases. Clin Immunol Immunopathol1991; 59: 314–321.
102.
102 Chaleomchan W Hemachudha T Sakulramrung R Deesomchok U . Anticardiolipin antibodies in patients with rabies vaccination induced neurological complications and other neurological diseases. J Neurol Sci1990; 96: 143–151.
103.
103 Marchiori PE Dos Reis M Quevedo ME . Cerebrospinal fluid and serum antiphospholipid antibodies in multiple sclerosis, Guillain–Barre syndrome and systemic lupus erythematosus. Arq Neuropsiquiatr1990; 48: 465–468.
104.
104 Karussis D Leker RR Ashkenazi A Abramsky O . A subgroup of multiple sclerosis patients with anticardiolipin antibodies and unusual clinical manifestations: do they represent a new nosological entity? Ann Neurol1998; 44: 629–634.
105.
105 Sugiyama Y Yamamoto T . Characterization of serum anti-phospholipid antibodies in patients with multiple sclerosis. Tohoku J Exp Med1996; 178: 203–215.
106.
106 Chapman J . The interface of multiple sclerosis and antiphospholipid antibodies. Thromb Res2004; 114: 477–481.
107.
107 IJdo, JW, Conti-Kelly, AM, Greco, P, et al. Anti-phospholipid antibodies in patients with multiple sclerosis and MS-like illnesses: MS or APS? Lupus1999; 8: 109–115.
108.
108 Arnold DL Matthews PM Francis G Antel J . Proton magnetic resonance spectroscopy of human brain in vivo in the evaluation of multiple sclerosis: assessment of the load of disease. Magn Reson Med1990; 14: 154–159.
109.
109 Arnold DL Matthews PM Francis GS O’Connor J Antel JP . Proton magnetic resonance spectroscopic imaging for metabolic characterization of demyelinating plaques. Ann Neurol1992; 31: 235–241.
110.
110 Hickey WF . Migration of hematogenous cells through the blood-brain barrier and the initiation of CNS inflammation. Brain Pathol1991; 1: 97–105.
111.
111 Brenner RE Munro PM Williams SC . The proton NMR spectrum in acute EAE: the significance of the change in the Cho:Cr ratio. Magn Reson Med1993; 29: 737–745.
112.
112 Narayana PA Doyle TJ Lai D Wolinsky JS . Serial proton magnetic resonance spectroscopic imaging, contrast- enhanced magnetic resonance imaging, and quantitative lesion volumetry in multiple sclerosis. Ann Neurol1998; 43: 56–71.
113.
113 Boggs JM Stamp D Moscarello MA . Comparison of two molecular species of ethanolamine plasmalogen in multiple sclerosis and normal myelin. Neurochem Res1982; 7: 953–964.
114.
114 Cunnane SC Ho SY Dore-Duffy P Ells KR Horrobin DF . Essential fatty acid and lipid profiles in plasma and erythrocytes in patients with multiple sclerosis. Am J Clin Nutr1989; 50: 801–806.
115.
115 Tong XW Xue QM . Alterations of serum phospholipids in patients with multiple sclerosis. Chin Med J (Engl)1993; 106: 650–654.
116.
116 Birgbauer E Rao TS Webb M . Lysolecithin induces demyelination in vitro in a cerebellar slice culture system. J Neurosci Res2004; 78: 157–166.
117.
117 Woodruff RH Franklin RJ . Demyelination and remyelination of the caudal cerebellar peduncle of adult rats following stereotaxic injections of lysolecithin, ethidium bromide, and complement/anti-galactocerebroside: a comparative study. Glia1999; 25: 216–228.
118.
118 Harrer MD von Büdingen HC Stoppini L . Live imaging of remyelination after antibody-mediated demyelination in an ex-vivo model for immune mediated CNS damage. Exp Neurol2009; 216: 431–438.
119.
119 Saher G Brügger B Lappe-Siefke C . High cholesterol level is essential for myelin membrane growth. Nat Neurosci2005; 8: 468–475.
120.
120 Popko B Dupree JL Coetzee T Suzuki K Suzuki K . Genetic analysis of myelin galactolipid function. Adv Exp Med Biol1999; 468: 237–244.
121.
121 Dupree JL Girault JA Popko B . Axo-glial interactions regulate the localization of axonal paranodal proteins. J Cell Biol1999; 147: 1145–1152.
122.
122 Marcus J Popko B . Galactolipids are molecular determinants of myelin development and axo-glial organization. Biochim Biophys Acta2002; 1573: 406–413.
123.
123 Han GS Wu WI Carman GM . The Saccharomyces cerevisiae Lipin homolog is a Mg2+-dependent phosphatidate phosphatase enzyme. J Biol Chem2006; 281: 9210–9218.
124.
124 Donkor J Sariahmetoglu M Dewald J Brindley DN Reue K . Three mammalian lipins act as phosphatidate phosphatases with distinct tissue expression patterns. J Biol Chem2007; 282: 3450–3457.
125.
125 Nadra K de Preux Charles AS Médard JJ . Phosphatidic acid mediates demyelination in Lpin1 mutant mice. Genes Dev2008; 22: 1647–1661.
126.
126 Kalyvas A Baskakis C Magrioti V . Differing roles for members of the phospholipase A2 superfamily in experimental autoimmune encephalomyelitis.Brain2009; 132: 1221–1235.
127.
127 Sun D Whitaker JN Huang Z . Myelin antigen-specific CD8+ T cells are encephalitogenic and produce severe disease in C57BL/6 mice. J Immunol2001; 166: 7579–7587.
128.
128 Karussis DM Vourka-Karussis U Lehmann D . Prevention and reversal of adoptively transferred, chronic relapsing experimental autoimmune encephalomyelitis with a single high dose cytoreductive treatment followed by syngeneic bone marrow transplantation. J Clin Invest1993; 92: 765–772.
129.
129 Rohowsky-Kochan C Molinaro D Cook SD . Cytokine secretion profile of myelin basic protein-specific T cells in multiple sclerosis. Mult Scler2000; 6: 69–77.
130.
130 Bielekova B Sung MH Kadom N Simon R McFarland H Martin R . Expansion and functional relevance of high-avidity myelin-specific CD4+ T cells in multiple sclerosis. J Immunol2004; 172: 3893–3904.
131.
131 Furuzawa-Carballeda J Vargas-Rojas MI Cabral AR . Autoimmune inflammation from the Th17 perspective. Autoimmun Rev2007; 6: 169–175.
132.
132 Weiner HL . A shift from adaptive to innate immunity: a potential mechanism of disease progression in multiple sclerosis. J Neurol2008; 255(Suppl. 1): 3–11.
133.
133 McFarland HF Martin R . Multiple sclerosis: a complicated picture of autoimmunity. Nat Immunol2007; 8: 913–919.
134.
134 O’Connor KC Bar-Or A Hafler DA . The neuroimmunology of multiple sclerosis: possible roles of T and B lymphocytes in immunopathogenesis. J Clin Immunol2001; 21: 81–92.
135.
135 Martin R McFarland HF McFarlin DE . Immunological aspects of demyelinating diseases. Annu Rev Immunol1992; 10: 153–187.
136.
136 Hohlfeld R Meinl E Weber F . The role of autoimmune T lymphocytes in the pathogenesis of multiple sclerosis. Neurology1995; 45: S33–S38.
137.
137 McLean BN Luxton RW Thompson EJ . A study of immunoglobulin G in the cerebrospinal fluid of 1007 patients with suspected neurological disease using isoelectric focusing and the Log IgG-Index. A comparison and diagnostic applications. Brain1990; 113(Pt 5): 1269–1289.
138.
138 Correale J de los Milagros Bassani Molinas M . Oligoclonal bands and antibody responses in multiple sclerosis. J Neurol2002; 249: 375–389.
139.
139 Antel J Bar-Or A . Roles of immunoglobulins and B cells in multiple sclerosis: from pathogenesis to treatment. J Neuroimmunol2006; 180: 3–8.
140.
140 Serafini B Rosicarelli B Franciotta D . Dysregulated Epstein-Barr virus infection in the multiple sclerosis brain. J Exp Med2007; 204: 2899–2912.
141.
141 Vartdal F Vandvik B Norrby E . Viral and bacterial antibody responses in multiple sclerosis. Ann Neurol1980; 8: 248–255.
142.
142 Vartdal F Vandvik B . Multiple sclerosis: subclasses of intrathecally synthesized IgG and measles and varicella zoster virus IgG antibodies. Clin Exp Immunol1983; 54: 641–647.
143.
143 Salmi A Reunanen M Ilonen J Panelius M . Intrathecal antibody synthesis to virus antigens in multiple sclerosis. Clin Exp Immunol1983; 52: 241–249.
144.
144 Burgoon MP Williamson RA Owens GP . Cloning the antibody response in humans with inflammatory CNS disease: isolation of measles virus-specific antibodies from phage display libraries of a subacute sclerosing panencephalitis brain. J Neuroimmunol1999; 94: 204–211.
145.
145 Cremer NE Johnson KP Fein G Likosky WH . Comprehensive viral immunology of multiple sclerosis. II. Analysis of serum and CSF antibodies by standard serologic methods. Arch Neurol1980; 37: 610–615.
146.
146 Wirguin I Brenner T Steinitz M Abramsky O . In vitro synthesis of antibodies to myelin antigens by Epstein-Barr virus-transformed B lymphocytes from patients with neurologic disorders. J Neurol Sci1991; 104: 92–96.
147.
147 Richert JR Robinson ED Reuben-Burnside CA . Measles virus-specific human T cell clones: studies of alloreactivity and antigenic cross-reactivity. J Neuroimmunol1988; 19: 59–68.
148.
148 Mameli G Astone V Arru G . Brains and peripheral blood mononuclear cells of multiple sclerosis (MS) patients hyperexpress MS-associated retrovirus/HERV-W endogenous retrovirus, but not human herpesvirus 6. J Gen Virol2007; 88: 264–274.
149.
149 Lünemann JD Edwards N Muraro PA . Increased frequency and broadened specificity of latent EBV nuclear antigen-1-specific T cells in multiple sclerosis. Brain2006; 129: 1493–1506.
150.
150 Oldstone MB . Molecular mimicry, microbial infection, and autoimmune disease: evolution of the concept. Curr Top Microbiol Immunol2005; 296: 1–17.
151.
151 Wucherpfennig KW . Mechanisms for the induction of autoimmunity by infectious agents. J Clin Invest2001; 108: 1097–1104.
152.
152 van Noort JM Bajramovic JJ Plomp AC van Stipdonk MJ . Mistaken self, a novel model that links microbial infections with myelin-directed autoimmunity in multiple sclerosis. J Neuroimmunol2000; 105: 46–57.
153.
153 Tejada-Simon MV Zang YC Hong J Rivera VM Zhang JZ . Cross-reactivity with myelin basic protein and human herpesvirus-6 in multiple sclerosis. Ann Neurol2003; 53: 189–197.
154.
154 Sospedra M Martin R . Molecular mimicry in multiple sclerosis. Autoimmunity2006; 39: 3–8.
155.
155 McCoy L Tsunoda I Fujinami RS . Multiple sclerosis and virus induced immune responses: autoimmunity can be primed by molecular mimicry and augmented by bystander activation. Autoimmunity2006; 39: 9–19.
156.
156 Hawa M Beyan H Leslie RD . Principles of autoantibodies as disease-specific markers. Autoimmunity2004; 37: 253–256.
157.
157 Archelos JJ Hartung HP . Pathogenetic role of autoantibodies in neurological diseases. Trends Neurosci2000; 23: 317–327.
158.
158 Kabat EA Glusman M Knaub V . Immunochemical estimation of albumin and gamma globulin in normal and pathological cerebrospinal fluid. Trans Am Neurol Assoc1948; 73: 93.
159.
159 Kabat EA Glusman M Knaub V . Quantitative estimation of the albumin and gamma-globulin in normal and pathological cerebrospinal fluid by immunochemical methods. Am J Clin Med1948; 4: 653–662.
160.
160 Rinaldi L Gallo P . Immunological markers in multiple sclerosis: tackling the missing elements. Neurol Sci2005; 26(Suppl. 4): S215–S217.
161.
161 Tumani H Teunissen C Sussmuth S Otto M Ludolph AC Brettschneider J . Cerebrospinal fluid biomarkers of neurodegeneration in chronic neurological diseases. Expert Rev Mol Diagn2008; 8: 479–494.
162.
162 Zifman E Amital H . Prediction of neurological diseases by using autoantibodies: wishful thinking come true. Isr Med Assoc J2008; 10: 29–31.
163.
163 Berger T Reindl M . Multiple sclerosis: disease biomarkers as indicated by pathophysiology. J Neurol Sci2007; 259: 21–26.
164.
164 Reindl M Khalil M Berger T . Antibodies as biological markers for pathophysiological processes in MS. J Neuroimmunol2006; 180: 50–62.
165.
165 Avasarala JR Cross AH Trotter JL . Oligoclonal band number as a marker for prognosis in multiple sclerosis. Arch Neurol2001; 58: 2044–2045.
166.
166 Izquierdo G Angulo S Garcia-Moreno JM . Intrathecal IgG synthesis: marker of progression in multiple sclerosis patients. Acta Neurol Scand2002; 105: 158–163.
167.
167 Menon KK Piddlesden SJ Bernard CC . Demyelinating antibodies to myelin oligodendrocyte glycoprotein and galactocerebroside induce degradation of myelin basic protein in isolated human myelin. J Neurochem1997; 69: 214–222.
168.
168 Fierz W Heininger K Schaefer B Toyka KV Linington C Lassmann H . Synergism in the pathogenesis of EAE induced by an MBP-specific T-cell line and monoclonal antibodies to galactocerebroside or a myelin oligodendroglial glycoprotein. Ann N Y Acad Sci1988; 540: 360–363.
169.
169 Menge T Lalive PH von Budingen HC Cree B Hauser SL Genain CP . Antibody responses against galactocerebroside are potential stage-specific biomarkers in multiple sclerosis. J Allergy Clin Immunol2005; 116: 453–459.
170.
170 Lubetzki C Lombrail P Hauw JJ Zalc B . Multiple sclerosis: rat and human oligodendrocytes are not the target for CSF immunoglobulins. Neurology1986; 36: 524–528.
171.
171 Gerhard W Taylor A Wroblewska Z Sandberg-Wollheim M Koprowski H . Analysis of a predominant immunoglobulin population in the cerebrospinal fluid of a multiple sclerosis patient by means of an anti-idiotypic hybridoma antibody. Proc Natl Acad Sci U S A1981; 78: 3225–3229.
172.
172 Quintana FJ Farez MF Viglietta V . Antigen microarrays identify unique serum autoantibody signatures in clinical and pathologic subtypes of multiple sclerosis. Proc Natl Acad Sci U S A2008; 105: 18889–18894.
173.
173 Lucchinetti CF Bruck W Rodriguez M Lassmann H . Distinct patterns of multiple sclerosis pathology indicates heterogeneity on pathogenesis. Brain Pathol1996; 6: 259–274.
174.
174 Ben-Nun A Wekerle H Cohen IR . Vaccination against autoimmune encephalomyelitis with T-lymphocyte line cells reactive against myelin basic protein. Nature1981; 292: 60–61.
175.
175 Wolf SD Dittel BN Hardardottir F Janeway CA . Experimental autoimmune encephalomyelitis induction in genetically B cell-deficient mice. J Exp Med1996; 184: 2271–2278.
176.
176 Zhang B Yamamura T Kondo T Fujiwara M Tabira T . Regulation of experimental autoimmune encephalomyelitis by natural killer (NK) cells. J Exp Med1997; 186: 1677–1687.
177.
177 Van Kaer L . Natural killer T cells as targets for immunotherapy of autoimmune diseases. Immunol Cell Biol2004; 82: 315–322.
178.
178 Linsen L Somers V Stinissen P . Immunoregulation of autoimmunity by natural killer T cells. Hum Immunol2005; 66: 1193–1202.
179.
179 Savage PB Teyton L Bendelac A . Glycolipids for natural killer T cells. Chem Soc Rev2006; 35: 771–779.
180.
180 Godfrey DI MacDonald HR Kronenberg M Smyth MJ Van Kaer L . NKT cells: what's in a name? Nat Rev Immunol2004; 4: 231–237.
181.
181 Godfrey DI Kronenberg M . Going both ways: immune regulation via CD1d-dependent NKT cells. J Clin Invest2004; 114: 1379–1388.
182.
182 Wilson SB Delovitch TL . Janus-like role of regulatory iNKT cells in autoimmune disease and tumour immunity. Nat Rev Immunol2003; 3: 211–222.
183.
183 Illes Z Kondo T Newcombe J Oka N Tabira T Yamamura T . Differential expression of NK T cell V alpha 24J alpha Q invariant TCR chain in the lesions of multiple sclerosis and chronic inflammatory demyelinating polyneuropathy. J Immunol2000; 164: 4375–4381.
184.
184 Demoulins T Gachelin G Bequet D Dormont D . A biased Valpha24+ T-cell repertoire leads to circulating NKT-cell defects in a multiple sclerosis patient at the onset of his disease. Immunol Lett2003; 90: 223–228.
185.
185 Araki M Kondo T Gumperz JE Brenner MB Miyake S Yamamura T . Th2 bias of CD4+ NKT cells derived from multiple sclerosis in remission. Int Immunol2003; 15: 279–288.
186.
186 De Libero G Mori L . Recognition of lipid antigens by T cells. Nat Rev Immunol2005; 5: 485–496.
187.
187 De Libero G Mori L . Mechanisms of lipid-antigen generation and presentation to T cells. Trends Immunol2006; 27: 485–492.
188.
188 Shamshiev A Donda A Prigozy TI . The alphabeta T cell response to self-glycolipids shows a novel mechanism of CD1b loading and a requirement for complex oligosaccharides. Immunity2000; 13: 255–264.
189.
189 Shamshiev A Gober HJ Donda A Mazorra Z Mori L De Libero G . Presentation of the same glycolipid by different CD1 molecules. J Exp Med2002; 195: 1013–1021.
190.
190 Gumperz JE Roy C Makowska A . Murine CD1d-restricted T cell recognition of cellular lipids. Immunity2000; 12: 211–221.
191.
191 Jahng A Maricic I Aguilera C Cardell S Halder RC Kumar V . Prevention of autoimmunity by targeting a distinct, noninvariant CD1d-reactive T cell population reactive to sulfatide. J Exp Med2004; 199: 947–957.
192.
192 Zhou D Mattner J Cantu C . Lysosomal glycosphingolipid recognition by NKT cells. Science2004; 306: 1786–1789.
193.
193 Wu DY Segal NH Sidobre S Kronenberg M Chapman PB . Cross-presentation of disialoganglioside GD3 to natural killer T cells. J Exp Med2003; 198: 173–181.
194.
194 Halder RC Jahng A Maricic I Kumar V . Mini review: immune response to myelin-derived sulfatide and CNS-demyelination. Neurochem Res2007; 32: 257–262.
195.
195 Mars LT Gautron AS Novak J . Invariant NKT cells regulate experimental autoimmune encephalomyelitis and infiltrate the central nervous system in a CD1d-independent manner. J Immunol2008; 181: 2321–2329.
196.
196 Winkler-Pickett R Young HA Cherry JM . In vivo regulation of experimental autoimmune encephalomyelitis by NK cells: alteration of primary adaptive responses. J Immunol2008; 180: 4495–4506.
197.
197 Singh AK Wilson MT Hong S . Natural killer T cell activation protects mice against experimental autoimmune encephalomyelitis. J Exp Med2001; 194: 1801–1811.
198.
198 Pal E Tabira T Kawano T Taniguchi M Miyake S Yamamura T . Costimulation-dependent modulation of experimental autoimmune encephalomyelitis by ligand stimulation of V alpha 14 NK T cells. J Immunol2001; 166: 662–668.
199.
199 Miyamoto K Miyake S Yamamura T . A synthetic glycolipid prevents autoimmune encephalomyelitis by inducing TH2 bias of natural killer T cells. Nature2001; 413: 531–534.
200.
200 Jahng AW Maricic I Pedersen B . Activation of natural killer T cells potentiates or prevents experimental autoimmune encephalomyelitis. J Exp Med2001; 194: 1789–1799.
201.
201 Furlan R Bergami A Cantarella D . Activation of invariant NKT cells by alphaGalCer administration protects mice from MOG35-55-induced EAE: critical roles for administration route and IFN-gamma. Eur J Immunol2003; 33: 1830–1838.
202.
202 O’Keeffe J Gately CM Counihan T . T-cells expressing natural killer (NK) receptors are altered in multiple sclerosis and responses to alpha-galactosylceramide are impaired. J Neurol Sci2008; 275: 22–28.
203.
203 De Libero G Macdonald HR Dellabona P . T cell recognition of lipids: quo vadis? Nat Immunol2007; 8: 223–227.
204.
204 Rauch J Gumperz J Robinson C . Structural features of the acyl chain determine self-phospholipid antigen recognition by a CD1d-restricted invariant NKT (iNKT) cell. J Biol Chem2003; 278: 47508–47515.
205.
205 McCarthy C Shepherd D Fleire S . The length of lipids bound to human CD1d molecules modulates the affinity of NKT cell TCR and the threshold of NKT cell activation. J Exp Med2007; 204: 1131–1144.
206.
206 De Libero G Mori L . How T cells get grip on lipid antigens. Curr Opin Immunol2008; 20: 96–104.
207.
207 Kawano T Cui J Koezuka Y . CD1d-restricted and TCR-mediated activation of valpha14 NKT cells by glycosylceramides. Science1997; 278: 1626–1629.
208.
208 Brossay L Naidenko O Burdin N Matsuda J Sakai T Kronenberg M . Structural requirements for galactosylceramide recognition by CD1-restricted NK T cells. J Immunol1998; 161: 5124–5128.
209.
209 Naidenko OV Koezuka Y Kronenberg M . CD1-mediated antigen presentation of glycosphingolipids. Microbes Infect2000; 2: 621–631.
210.
210 Ben-Hur T Goldman SA . Prospects of cell therapy for disorders of myelin. Ann N Y Acad Sci2008; 1142: 218–249.
211.
211 Warrington AE Bieber AJ Ciric B . Immunoglobulin-mediated CNS repair. J Allergy Clin Immunol2001; 108: S121–S125.
212.
212 Warrington AE Rodriguez M . Remyelination-promoting human IgMs: developing a therapeutic reagent for demyelinating disease. Curr Top Microbiol Immunol2008; 318: 213–239.
213.
213 Paz Soldan MM Warrington AE Bieber AJ . Remyelination-promoting antibodies activate distinct Ca2+ influx pathways in astrocytes and oligodendrocytes: relationship to the mechanism of myelin repair. Mol Cell Neurosci2003; 22: 14–24.
214.
214 Lang W Rodriguez M Lennon VA Lampert PW . Demyelination and remyelination in murine viral encephalomyelitis. Ann N Y Acad Sci1984; 436: 98–102.
215.
215 Huang DW McKerracher L Braun PE David S . A therapeutic vaccine approach to stimulate axon regeneration in the adult mammalian spinal cord. Neuron1999; 24: 639–647.
216.
216 Rodriguez M Lennon VA Benveniste EN Merrill JE . Remyelination by oligodendrocytes stimulated by antiserum to spinal cord. J Neuropathol Exp Neurol1987; 46: 84–95.
217.
217 Warrington AE Asakura K Bieber AJ . Human monoclonal antibodies reactive to oligodendrocytes promote remyelination in a model of multiple sclerosis. Proc Natl Acad Sci U S A2000; 97: 6820–6825.
218.
218 Bieber AJ Warrington A Asakura K . Human antibodies accelerate the rate of remyelination following lysolecithin-induced demyelination in mice. Glia2002; 37: 241–249.
219.
219 Pavelko KD van Engelen BG Rodriguez M . Acceleration in the rate of CNS remyelination in lysolecithin-induced demyelination. J Neurosci1998; 18: 2498–2505.
220.
220 Miller DJ Bright JJ Sriram S Rodriguez M . Successful treatment of established relapsing experimental autoimmune encephalomyelitis in mice with a monoclonal natural autoantibody. J Neuroimmunol1997; 75: 204–209.
221.
221 Miller DJ Sanborn KS Katzmann JA Rodriguez M . Monoclonal autoantibodies promote central nervous system repair in an animal model of multiple sclerosis. J Neurosci1994; 14: 6230–6238.
222.
222 Asakura K Miller DJ Murray K Bansal R Pfeiffer SE Rodriguez M . Monoclonal autoantibody SCH94.03, which promotes central nervous system remyelination, recognizes an antigen on the surface of oligodendrocytes. J Neurosci Res1996; 43: 273–281.
223.
223 Mitsunaga Y Ciric B Van Keulen V . Direct evidence that a human antibody derived from patient serum can promote myelin repair in a mouse model of chronic-progressive demyelinating disease. FASEB J2002; 16: 1325–1327.
224.
224 Rodriguez M Warrington AE Pease LR . Invited article: human natural autoantibodies in the treatment of neurologic disease. Neurology2009; 72: 1269–1276.
225.
225 Duncan ID . Glial cell transplantation and remyelination of the central nervous system. Neuropathol Appl Neurobiol1996; 22: 87–100.
226.
226 Howe CL Bieber AJ Warrington AE Pease LR Rodriguez M . Antiapoptotic signaling by a remyelination-promoting human antimyelin antibody. Neurobiol Dis2004; 15: 120–131.
227.
227 Warrington AE Bieber AJ Ciric B Pease LR Van Keulen V Rodriguez M . A recombinant human IgM promotes myelin repair after a single, very low dose. J Neurosci Res2007; 85: 967–976.
228.
228 Pirko I Ciric B Gamez J . A human antibody that promotes remyelination enters the CNS and decreases lesion load as detected by T2-weighted spinal cord MRI in a virus-induced murine model of MS. FASEB J2004; 18: 1577–1579.
229.
229 Yu RK Ariga T . The role of glycosphingolipids in neurological disorders. Mechanisms of immune action. Ann N Y Acad Sci1998; 845: 285–306.
